Ben Taylor Sells 7,956 Shares of Recursion Pharmaceuticals (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Ben Taylor sold 7,956 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $3.39, for a total value of $26,970.84. Following the completion of the transaction, the chief financial officer owned 1,180,318 shares in the company, valued at $4,001,278.02. This trade represents a 0.67% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Recursion Pharmaceuticals Stock Performance

Recursion Pharmaceuticals stock traded down $0.10 during mid-day trading on Wednesday, reaching $3.32. 14,353,744 shares of the company were exchanged, compared to its average volume of 19,579,018. The firm’s 50-day simple moving average is $3.98 and its two-hundred day simple moving average is $4.56. Recursion Pharmaceuticals, Inc. has a twelve month low of $2.98 and a twelve month high of $7.18. The firm has a market cap of $1.75 billion, a PE ratio of -2.24 and a beta of 0.97. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.50 and a current ratio of 5.50.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, February 25th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.07. Recursion Pharmaceuticals had a negative return on equity of 63.98% and a negative net margin of 863.37%.The business had revenue of $35.54 million for the quarter, compared to analyst estimates of $24.56 million. During the same quarter in the previous year, the company posted ($0.53) earnings per share. The company’s revenue for the quarter was up 671.7% compared to the same quarter last year. Equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on RXRX shares. JPMorgan Chase & Co. upgraded shares of Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $10.00 to $11.00 in a research report on Wednesday, December 17th. Needham & Company LLC reiterated a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Thursday, February 26th. Wall Street Zen raised shares of Recursion Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Thursday, January 22nd. Finally, Morgan Stanley set a $11.00 target price on Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and a consensus price target of $9.40.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in RXRX. Norges Bank acquired a new stake in shares of Recursion Pharmaceuticals in the second quarter valued at about $16,040,000. Bank Pictet & Cie Europe AG acquired a new position in Recursion Pharmaceuticals during the third quarter worth about $7,954,000. ARK Investment Management LLC increased its holdings in Recursion Pharmaceuticals by 1.7% in the third quarter. ARK Investment Management LLC now owns 33,545,499 shares of the company’s stock valued at $163,702,000 after buying an additional 556,868 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Recursion Pharmaceuticals by 10.3% during the 3rd quarter. Vanguard Group Inc. now owns 39,780,153 shares of the company’s stock valued at $194,127,000 after acquiring an additional 3,708,975 shares during the period. Finally, Rafferty Asset Management LLC lifted its position in shares of Recursion Pharmaceuticals by 110.6% during the 3rd quarter. Rafferty Asset Management LLC now owns 750,191 shares of the company’s stock valued at $3,661,000 after acquiring an additional 394,022 shares during the period. 89.06% of the stock is owned by institutional investors and hedge funds.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.